ENDO 2025: The publications reflect growing consensus that integration of endocrine screening into standard clinical workflows is essential for early risk detection and long-term disease prevention.
Baxdrostat met the primary and all secondary endpoints, setting up a first regulatory filing for the selective aldosterone synthase inhibitor, according to AstraZeneca.
ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.